Form 4: BioCryst Pharmaceuticals Director Amy E. McKee Reports Stock and Option Grants

Director Amy E. McKee reported the acquisition of restricted stock units and stock options in BioCryst Pharmaceuticals, according to a Form 4 filing.

Summary

• Amy E. McKee, a director of BioCryst Pharmaceuticals, reported a transaction involving the acquisition of securities.
• On June 12, 2024, McKee acquired 6,820 shares of common stock and was granted options for 49,933 shares.
• The common stock was acquired through an automatic non-employee director grant of Restricted Stock Units (RSUs) at a price of $0, which will vest on the first anniversary of the grant date.
• The stock options were also granted automatically as part of the non-employee director compensation policy, with an exercise price of $6.30, exercisable from June 12, 2025, and expiring on June 12, 2034.
• Following the reported transaction, McKee directly owns 36,431 shares of common stock and options for 49,933 shares.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive as it reflects standard compensation practices that align director interests with shareholders. There are no indications of negative events or concerns.

Positives

• The grant of stock options and restricted stock units to a director aligns their interests with those of the shareholders.
• The vesting schedule for the restricted stock units encourages long-term commitment from the director.

Industry Context

This filing is a routine disclosure of stock and option grants to a company director, which is a common practice in publicly traded companies to incentivize and align the interests of directors with shareholders.

Comparison to Industry Standards

• Director compensation packages, including stock options and restricted stock units, are standard practice among publicly traded pharmaceutical companies.
• Companies like Amgen, Gilead Sciences, and Regeneron Pharmaceuticals also utilize similar compensation strategies to attract and retain qualified board members.
• The specific number of shares and option grants would be benchmarked against companies of similar market capitalization and stage of development within the biotechnology sector.

Stakeholder Impact

• The stock and option grants to the director align their interests with those of the shareholders, potentially leading to decisions that benefit the company's long-term value.
• Employees may view the director's compensation as a sign of the company's commitment to its leadership.

Key Dates